H.C. Wainwright raised the firm’s price target on Femasys to $13 from $12 and keeps a Buy rating on the shares. Femasys reported Q1 diagnostics sales of $0.27M, which were 27% higher than 4Q23 sales, and H.C. Wainwright is expecting an initial boost in sales for FemaSeed after the 2024 American College of Obstetricians and Gynecologists, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FEMY:
- Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
- Femasys expands commercial management team
- Femasys Releases Updated Investor Presentation Information
- Femasys CEO meets with members of Congress to raise awareness
- Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives